A Phase I-II Trial of Combined PKCι and mTOR Inhibition for Patients With Advanced or Recurrent Lung Cancer (NSCLC and SCLC) Without Standard Treatment Options
Phase of Trial: Phase I/II
Latest Information Update: 02 Sep 2016
At a glance
- Drugs Auranofin (Primary) ; Sirolimus (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 25 Aug 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Jul 2017.
- 19 Apr 2016 Planned primary completion date changed from 1 Mar 2015 to 1 Mar 2017.
- 27 Mar 2013 Planned End Date changed from 1 Dec 2013 to 1 Aug 2014 as reported by ClinicalTrials.gov.